GlassScriptPhysician profile
Thomas E Merriman
NPI 1134179054
$7,401.39
in general payments reported to CMS, 2019-2025
25 companies · $1,216 in 2025
The $1,216 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,161 · 2020: $369 · 2021: $416 · 2022: $1,769 · 2023: $1,322 · 2024: $1,148 · 2025: $1,216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,291 · Travel and Lodging: $395.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,291.26 |
| Travel and Lodging | $395.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,520.26 | 2019-2025 | Proclaim, Eterna, Ionicrf |
| Medtronic, INC. | $1,090.31 | 2021-2023 | Vanta Adaptivestim |
| Medtronic USA, INC. | $592.37 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $310.70 | 2019-2024 | Xtampza |
| Amgen INC. | $116.27 | 2019 | |
| Biodelivery Sciences International, INC. | $86.00 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $79.85 | 2020-2021 | |
| Abbvie INC. | $74.40 | 2021-2024 | |
| Scilex Pharmaceuticals INC. | $72.33 | 2020-2021 | |
| Pfizer INC. | $67.11 | 2019 | |
| Spr Therapeutics, INC | $62.74 | 2024 | Sprint Pns System |
| Daiichi Sankyo INC. | $52.58 | 2019 | |
| Supernus Pharmaceuticals, INC. | $47.22 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $31.47 | 2019 | |
| Pacira Therapeutics, INC. | $27.76 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $25.40 | 2025 | Intracept |
| Epimed International, INC | $24.50 | 2019 | |
| Si-Bone, INC. | $19.21 | 2019 | |
| Ironshore Pharmaceuticals INC. | $17.92 | 2020 | |
| Upsher-Smith Laboratories LLC | $16.44 | 2019 | |
| Baudax Bio INC. | $16.23 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.20 | 2019 | |
| Zyla Life Sciences, INC. | $12.98 | 2019 | |
| Nevro Corp. | $11.84 | 2019 | |
| Vertiflex, INC. | $11.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Merriman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.